Abstract
Efforts to identify and treat individuals with elevated blood cholesterol levels have increased dramatically in recent years. The bile acid sequestrants (cholestyramine, colestipol) and nicotinic acid have been the mainstays of pharmacologic therapy for patients with phenotype(s) IIA and IIB hyperlipoproteinemia, but produce symptomatic side effects in a high percentage of patients. Clinical trials with a new class of cholesterol-lowering drugs, the HMG-CoA reductase inhibitors, have consistently demonstrated a dose-dependent reduction in total and low-density lipoprotein cholesterol levels of up to 30% and 40%, respectively. Symptomatic side effects requiring withdrawal of treatment have been uncommon, but the incidences of opacification of the ocular lens and hepatoxicity remain to be defined. Lovastatin is the first HMG-CoA reductase inhibitor commercially available in the United States. Its efficacy alone, and in combination with the bile acid sequestrants, is reviewed in this report.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
